BMS Licenses Innate Pharma’s Phase I Immuno-Oncology Monoclonal Antibody
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 7 (Table of Contents)
Published: 15 Jul-2011
DOI: 10.3833/pdr.v2011.i7.1496 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bristol-Myers Squibb (BMS) has licensed exclusive global rights to develop and commercialise Innate Pharma’s Phase I immuno-oncology antibody, IPH 2102, which uses the immune system to fight tumours...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS